Medine.co.uk

Otrivine Extra Dual Relief 0.5mg/Ml 0.6mg/Ml Nasal Spray

Informations for option: Otrivine Extra Dual Relief 0.5mg/Ml 0.6mg/Ml Nasal Spray, show other option
Document: leaflet MAH BRAND_PL 44673-0153 change

Package leaflet: Information for the user

Otrivine Extra Dual Relief 0.5 mg/ml, 0.6 mg/ml nasal spray, solution Xylometazoline hydrochloride/Ipratropium bromide

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

Always use this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you.

-    Keep this leaflet. You may need to read it again.

-    Ask your pharmacist if you need more information or advice.

-    If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

-    You must talk to a doctor if you do not feel better or if you feel worse.

What is in this leaflet

1.    What Otrivine Extra Dual Relief is and what it is used for

2.    What you need to know before you use Otrivine Extra Dual Relief

3.    How to use Otrivine Extra Dual Relief

4.    Possible side effects

5 How to store Otrivine Extra Dual Relief 6. Contents of the pack and other information

1.    What Otrivine Extra Dual Relief is and what it is used for

Otrivine Extra Dual Relief is a combination medicinal product consisting of two different substances. One of the active ingredients helps against runny nose, the other has a decongesting effect.

Otrivine Extra Dual Relief is used for the treatment of nasal congestion with runny nose (rhinorrhea) in connection with common colds.

2.    What you need to know before you use Otrivine Extra Dual Relief Do not use Otrivine Extra Dual Relief

-    In children below 18 years of age, as adequate information on safety and efficacy is not available

-    If you are allergic to xylometazoline hydrochloride or ipratropium bromide or any of the other ingredients of this medicine (listed in section 6)

-    If you are allergic to atropine or similar substances, e.g. hyoscyamine and scopolamine

-    If you had your pituitary gland removed by surgery carried out through the nose

-    If you have had brain surgery where the operation was carried out through the nose or mouth

-    If you suffer from glaucoma (increased pressure in the eye)

-    If you have a very dry nose (inflammatory nasal dryness, rhinitis sicca)

Warnings and precautions

Talk to your doctor or pharmacist before using Otrivine Extra Dual Relief if you suffer from:

-    Heart disease

-    Raised blood pressure

-    Diabetes

-    An overactive thyroid gland (hyperthyroidism)

-    Difficulty in urinating and/or an enlarged prostate gland

-    Narrow-angle glaucoma

-    A tendency to have nosebleeds

-    Obstruction of the gut (small intestine)

-    Cystic fibrosis

-    Benign tumour of the adrenal gland that produces high amounts of adrenaline and nor-adrenaline (phaeochromocytoma) or a particular sensitivity to adrenaline and nor-adrenaline as you may experience dizziness, tremor, rapid heart rate, raised blood pressure and sleeplessness

Immediate hypersensitivity (allergic reaction) may occur. This may be seen as itchy red rash with raised inflammation of the skin (hives), difficulty breathing or speaking, difficulty swallowing due to swelling of the lips, face or throat. These symptoms may appear individually or all combined as a severe allergic reaction. If this occurs, immediately STOP using Otrivine Extra Dual Relief (see section 4).

Otrivine Extra Dual Relief should not be used for more than 7 consecutive days. If symptoms persist, consult a doctor. Prolonged or excessive use may cause stuffiness in the nose to return or worsen and swelling of the nasal mucosa.

Avoid spraying Otrivine Extra Dual Relief in or around the eyes. If this happens thoroughly rinse the eyes with cold water. Your vision may become temporarily blurred and the eye irritated, painful and red. If this happens contact your doctor for advice. Worsening of narrow-angle glaucoma may also occur

Children and adolescents

Otrivine Extra Dual Relief is not recommended for use in children and adolescents below 18 years of age as adequate information on safety and efficacy is not available.

Other medicines and Otrivine Extra Dual Relief

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. It is particularly important that you mention the following:

-    Monoamine oxidase inhibitors (used for treatment of depression). If you are taking or have taken these in the last two weeks, dangerous rises of the blood pressure may occur

-    Tri-cyclic and tetra-cyclic antidepressants (if you are taking or have taken these in the last two weeks)

-    Medicines used for travel sickness (medicines containing anticholinergic substances)

-    Medicines used for gut disorders (particularly those for abnormal motility) (medicines containing anticholinergic substances)

If you use any of the above medicines, consult a doctor before using Otrivine Extra Dual Relief . Pregnancy and breast-feeding

Otrivine Extra Dual Relief should not be used during pregnancy unless your doctor recommends it.

During breast-feeding, Otrivine Extra Dual Relief should not be used unless your doctor decides the advantages outweigh the potential risks to the infant.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machines:

Visual disturbances (including blurred vision and dilation of the pupil), dizziness and fatigue have been reported with Otrivine Extra Dual Relief . If affected, you should avoid driving, operating machinery or taking part in activities where these symptoms may put yourself or others at risk.

3. How to use Otrivine Extra Dual Relief

Always use this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose is:

Adults: One puff in each nostril as needed, up to 3 times daily for maximum 7 days. Leave at least 6 hours between two doses. Do not exceed 3 applications daily into each nostril.

It is recommended that you stop treatment with Otrivine Extra Dual Relief as soon as your symptoms improve, even if this is sooner than 7 days, in order to minimize the risk of adverse reactions.

If you think the effect of Otrivine Extra Dual Relief is too strong or too weak, consult your doctor or pharmacist.

Instructions for use:

•    Always blow your nose before using the nasal spray

•    Remove the dust cap

•    Do not cut the nozzle. The metered dose spray is ready to prime before use


•    Before the first application, prime the pump by pumping 4 times. Once primed the pump will normally remain charged throughout regular daily treatment periods. Should the spray not be ejected during the full actuation stroke, or if the product has not been used for longer than 6 days, the pump will need to be reprimed with 4 pumps as initially performed

•    Hold the bottle upright

•    Bend your head slightly forward

•    Close one nostril by placing your finger against the side of your nose and insert the spray tip into the other nostril. Press the pump quickly while inhaling through the nose

•    Repeat this procedure in the other nostril

The effect occurs within 5-15 minutes.

Avoid spraying Otrivine Extra Dual Relief in or around the eyes.

If you use more Otrivine Extra Dual Relief than you should:

If you, or someone else, have taken more medicine than you should, contact your doctor, hospital or emergency room for assessment of the risk. It is advisable to take this leaflet, bottle or pack with you.

This is particularly important for children who are more likely to develop adverse events than adults. Symptoms of overdose are severe dizziness, sweating, severely lowered body temperature, headache, slow heartbeat, rapid heartbeat, impaired breathing, coma, convulsion, hypertension (high blood pressure) which may be followed by hypotension (low blood pressure).

Other symptoms may be dry mouth, difficulties focusing with the eye and hallucinations.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

STOP using Otrivine Extra Dual Relief and seek medical help immediately if you have any of the following:

-    Palpitations and increased heart rate (affects less than 1 in 100 people)

-    Signs of an allergic reaction as difficulty breathing, speaking or swallowing; swelling of the face, lips, tongue or throat; severe itching of the skin, with a red rash or raised bumps (frequency not known cannot be estimated from available data)

-    Disturbances of vision (including blurred vision, worsening of glaucoma or increased pressure in the eye), rainbow-coloured circles/haloes around bright lights and/or eye pain (frequency not known cannot be estimated from available data)

The most common side effects are nose bleeding and nasal dryness. Many of the side effects reported are also symptoms of common cold.

Very common side effects (may affect more than 1 in 10 people):

•    Nose bleeding, nasal dryness

Common side effects (may affect up to 1 in 10 people):

•    Nasal discomfort, congestion of the nose, dry and irritated throat, pain in the nose

•    Dry mouth

•    Altered taste sensation, headache

Uncommon (may affect up to 1 in 100 people):

•    Nasal ulcer, sneezing, pain in the throat, cough, hoarseness

•    Stomach upsets, nausea

•    Altered smell sensation, dizziness, shakiness

•    Discomfort, tiredness

•    Sleeplessness

•    Irritation of the eyes, dry eyes

Rare (may affect up to 1 in 1,000 people):

•    Runny nose

Frequency not known (cannot be estimated from available data):

•    Rash, hives

•    Discomfort around the nose

•    Discomfort in the chest, thirst

•    Sudden spam of throat muscle

•    Irregular pulse

•    Difficulties focusing with the eyes, dilation of the pupils

•    Itching

•    Difficulties emptying the bladder.

In order to minimise the risk of side effects such as nose bleeding and other effects on the nose, it is recommended that you stop treatment with Otrivine Extra Dual Relief when your symptoms improve even if this is sooner than 7 days.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Otrivine Extra Dual Relief

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.

Do not freeze.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information What Otrivine Extra Dual Relief contains

The active substances are xylometazoline hydrochloride and ipratropium bromide.

1 ml contains 0.5 mg xylometazoline hydrochloride and 0.6 mg ipratropium bromide.

1 puff contains 70 micrograms xylometazoline hydrochloride and 84 micrograms ipratropium bromide. The other ingredients are disodium edetate, glycerol (85%), purified water, sodium hydroxide and hydrochloric acid.

What Otrivine Extra Dual Relief looks like and contents of the pack

Otrivine Extra Dual Relief is a clear solution.

The bottle contains approximately 70 puffs.

Otrivine Extra Dual Relief is available as a 10 ml nasal spray with a metered-dose spray pump. Marketing Authorisation Holder

GlaxoSmithKline Consumer Healthcare (UK) Trading Limited,

Brentford,

TW8 9GS,

U.K.

Manufacturer

Novartis Consumer Health Park View Riverside way Watchmoor Park Camberley, Surrey GU15 3YL

This medicinal product is authorised in the Member States of the EEA under the following names:

AT

Otrivin Duo 0,5 mg/ml + 0,6 mg/ml Nasenspray, Losung

BE

Otrivine Duo 0,5mg/ml + 0,6mg/ml neusspray oplossing

BG

Otrivin Extra 0.5 mg/ml + 0.6 mg/ml nasal spray, solution

CY

Otrivin Advance

CZ

Otrivin Rhinostop

DE

Otriven Duo mit Xylometazolin und Ipratropium

DK

Otrivin Comp n^sespray, oplosning

EE

Otrivin Total

EL

Otrivin Advance

ES

Otriduo 0,5mg/ml + 0,6mg/ml pulverizacion nasal

FI

Otrivin Comp 0,5mg/ml + 0,6mg/ml nenasumute, liuos

HU

Otrivin Plus 0,5mg/ml + 0,6mg/ml oldatos orrspray

IE    Otrivine Extra Dual Relief 0.5mg/ml, 0.6mg/ml Nasal Spray

IS    Otrivin Comp 0,5mg/ml + 0,6mg/ml nefuoi lausn

IT    Otriduo 0,5mg/ml + 0,6mg/ml spray nasale, soluzione

LT    OtriDuo 0,5 mg/ml + 0,6 mg/ml nosies purskalas, tirpalas

LU    Otrivine Duo